Mucin-Type O-GalNAc Glycosylation in Health and Disease
- PMID: 34495529
- DOI: 10.1007/978-3-030-70115-4_2
Mucin-Type O-GalNAc Glycosylation in Health and Disease
Erratum in
-
Correction to: Mucin-Type O-GalNAc Glycosylation in Health and Disease.Adv Exp Med Biol. 2021;1325:C1-C2. doi: 10.1007/978-3-030-70115-4_18. Adv Exp Med Biol. 2021. PMID: 35941349 No abstract available.
Abstract
Mucin-type GalNAc O-glycosylation is one of the most abundant and unique post-translational modifications. The combination of proteome-wide mapping of GalNAc O-glycosylation sites and genetic studies with knockout animals and genome-wide analyses in humans have been instrumental in our understanding of GalNAc O-glycosylation. Combined, such studies have revealed well-defined functions of O-glycans at single sites in proteins, including the regulation of pro-protein processing and proteolytic cleavage, as well as modulation of receptor functions and ligand binding. In addition to isolated O-glycans, multiple clustered O-glycans have an important function in mammalian biology by providing structural support and stability of mucins essential for protecting our inner epithelial surfaces, especially in the airways and gastrointestinal tract. Here the many O-glycans also provide binding sites for both endogenous and pathogen-derived carbohydrate-binding proteins regulating critical developmental programs and helping maintain epithelial homeostasis with commensal organisms. Finally, O-glycan changes have been identified in several diseases, most notably in cancer and inflammation, where the disease-specific changes can be used for glycan-targeted therapies. This chapter will review the biosynthesis, the biology, and the translational perspectives of GalNAc O-glycans.
Keywords: Cancer; Carbohydrate-binding proteins; GalNAc; Glycans; Mucins; Proprotein processing.
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Similar articles
-
Structural and Quantitative Characterization of Mucin-Type O-Glycans and the Identification of O-Glycosylation Sites in Bovine Submaxillary Mucin.Biomolecules. 2020 Apr 20;10(4):636. doi: 10.3390/biom10040636. Biomolecules. 2020. PMID: 32326134 Free PMC article.
-
Chemoenzymatic modular assembly of O-GalNAc glycans for functional glycomics.Nat Commun. 2021 Jun 11;12(1):3573. doi: 10.1038/s41467-021-23428-x. Nat Commun. 2021. PMID: 34117223 Free PMC article.
-
Diverse glycosylation of MUC1 and MUC2: potential significance in tumor immunity.J Biochem. 1999 Dec;126(6):975-85. doi: 10.1093/oxfordjournals.jbchem.a022565. J Biochem. 1999. PMID: 10578046 Review.
-
Cellular O-Glycome Reporter/Amplification (CORA): Analytical and Preparative Tools to Study Mucin-Type O-Glycans of Living Cells.Curr Protoc. 2021 Jun;1(6):e142. doi: 10.1002/cpz1.142. Curr Protoc. 2021. PMID: 34101390
-
Molecular Recognition of GalNAc in Mucin-Type O-Glycosylation.Acc Chem Res. 2023 Mar 7;56(5):548-560. doi: 10.1021/acs.accounts.2c00723. Epub 2023 Feb 23. Acc Chem Res. 2023. PMID: 36815693 Free PMC article. Review.
Cited by
-
Structural and mechanistic insights into the cleavage of clustered O-glycan patches-containing glycoproteins by mucinases of the human gut.Nat Commun. 2022 Jul 26;13(1):4324. doi: 10.1038/s41467-022-32021-9. Nat Commun. 2022. PMID: 35882872 Free PMC article.
-
Glycoengineered keratinocyte library reveals essential functions of specific glycans for all stages of HSV-1 infection.Nat Commun. 2023 Nov 2;14(1):7000. doi: 10.1038/s41467-023-42669-6. Nat Commun. 2023. PMID: 37919266 Free PMC article.
-
Mass Spectrometry Strategies for O-Glycoproteomics.Cells. 2024 Feb 25;13(5):394. doi: 10.3390/cells13050394. Cells. 2024. PMID: 38474358 Free PMC article. Review.
-
A Comprehensive Analysis of Tn and STn Antigen Expression in Esophageal Adenocarcinoma.Cancers (Basel). 2024 Jan 5;16(2):240. doi: 10.3390/cancers16020240. Cancers (Basel). 2024. PMID: 38254730 Free PMC article.
-
Siglec Signaling in the Tumor Microenvironment.Front Immunol. 2021 Dec 13;12:790317. doi: 10.3389/fimmu.2021.790317. eCollection 2021. Front Immunol. 2021. PMID: 34966391 Free PMC article. Review.
References
-
- Abuli A, Fernandez-Rozadilla C, Alonso-Espinaco V, Munoz J, Gonzalo V, Bessa X, Gonzalez D, Clofent J, Cubiella J, Morillas JD, Rigau J, Latorre M, Fernandez-Banares F, Pena E, Riestra S, Paya A, Jover R, Xicola RM, Llor X, Carvajal-Carmona L, Villanueva CM, Moreno V, Pique JM, Carracedo A, Castells A, Andreu M, Ruiz-Ponte C, Castellvi-Bel S, Gastrointestinal Oncology Group of the Spanish Gastroenterological Association (2011) Case-control study for colorectal cancer genetic susceptibility in EPICOLON: previously identified variants and mucins. BMC Cancer 11:339 - PubMed - PMC - DOI
-
- Alexander WS, Viney EM, Zhang JG, Metcalf D, Kauppi M, Hyland CD, Carpinelli MR, Stevenson W, Croker BA, Hilton AA, Ellis S, Selan C, Nandurkar HH, Goodnow CC, Kile BT, Nicola NA, Roberts AW, Hilton DJ (2006) Thrombocytopenia and kidney disease in mice with a mutation in the C1galt1 gene. Proc Natl Acad Sci U S A 103:16442–16447 - PubMed - PMC - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources